bookmark:
connotea
::
del.icio.us
::digg
::furl
::reddit
::yahoo::
redux [06.29.00]
Yahoo! News Celera to Shift Focus to Patentable Discoveries
"A day after Monday's announcement that it had sequenced the entire human genome, Celera Genomics said on Tuesday that it will turn its attention to other, potentially more profitable, endeavors.
"Speaking to investors during a conference call, Tony L. White, chairman of the PE Corporation, Celera's parent company, said that ``all of the energy'' of the genomics unit will be directed toward discovery efforts "that are subject to intellectual property protection.''"
"The move toward discovery efforts represents ``a shift from what we've been doing,'' White acknowledged. "Our focus from the formation of the company 2 years ago was to build a significant bioinformatics presence,'' he said, "but we have the money to pursue a much more grandiose strategy now and we intend to do that.''"redux [02.18.00]Forbes Celera's Worth Still Up In The Air
"Great discoveries do not necessarily make great businesses. Businesses have to sell something. Celera Genomics doesn't sell or make anything tangible. It hawks service and information. It sells access to lists of genes and computers that can sort through those messy lists. Samuel Broder, the company's executive vice president and chief medical officer, makes Celera sound like some kind of consulting company, or perhaps a library."
"Venter's quest could be a fable, with all sorts of morals about the power of capitalism and the importance of a single, brilliant, willful individual who used the market to shake the ivory towers of science. But those morals only hold if Celera succeeds, if business and science blend to propel the company into the future with breathtaking speed without rocketing it into the realities of the marketplace. Celera could become one of the great business success stories. It could also be a financial train wreck."
Right now, that makes it a very volatile stock."
Science SNP Mappers Confront Reality and Find It Daunting
[summary - can be viewed for free once registered]
"The genetic markers called SNPs have been widely touted as the key to personalized medicine, with drugs tailored to an individual's genotype and simple tests to determine one's risk of specific diseases. But a closed meeting held last week, sponsored by the SNP Consortium and the U.S. National Human Genome Research Institute, concluded that those promises may be harder to achieve than expected, and that more SNPs may be required to track down a particular disease gene than previously estimated.”
“Bioinformatics will be at the core of biology in the 21st century. In fields ranging from structural biology to genomics to biomedical imaging, ready access to data and analytical tools are fundamentally changing the way investigators in the life sciences conduct research and approach problems. Complex, computationally intensive biological problems are now being addressed and promise to significantly advance our understanding of biology and medicine. No biological discipline will be unaffected by these technological breakthroughs.”
BIOINFORMATICS IN THE 21st CENTURY
biospace
/
genomeweb
/
bio-it world
/
scitechdaily
/
biomedcentral
/
the panda's thumb
/
bioinformatics.org
/
nodalpoint
/
flags and lollipops
/
on genetics
/
a bioinformatics blog
/
andrew dalke
/
the struggling grad student
/
in the pipeline
/
gene expression
/
free association
/
pharyngula
/
the personal genome
/
genetics and public health blog
/
the medical informatics weblog
/
linuxmednews
/
nanodot
/
complexity digest
/
eyeforpharma
/
nsu
/
nyt science
/
bbc scitech
/
newshub
/
biology news net
/
informatics review
/
stanford
/
bmj info in practice
/
bmj info in practice
/
look snazzy and support the site at the same time by buying some snowdeal schwag !
valid xhtml 1.0?
This site designed by
Eric C. Snowdeal III
.
© 2000-2005